eyepoint
pharmaceuticals
announces
preliminary
net
product
revenue
third
quarter
net
product
revenues
estimated
million
healthcare
facilities
began
reopening
closures
sequential
increase
underlying
customer
demand
yutiq
dexycu
watertown
globe
newswire
eyepoint
pharmaceuticals
nasdaq
eypt
pharmaceutical
company
committed
developing
commercializing
innovative
ophthalmic
products
today
reported
preliminary
unaudited
net
product
revenue
estimates
third
quarter
third
quarter
ended
september
net
product
revenues
estimated
million
compared
net
product
revenues
million
reported
second
quarter
ended
june
increase
driven
sequential
increase
customer
demand
quarter
regions
united
states
began
reopening
following
closures
pleased
see
continued
return
customer
demand
yutiq
dexycu
third
quarter
healthcare
facilities
business
resumed
patient
treatment
said
nancy
lurker
president
chief
executive
officer
eyepoint
pharmaceuticals
customer
demand
trends
third
quarter
exceeded
second
quarter
approaching
pandemic
levels
highlighting
promising
recovery
believe
products
offer
physicians
distinct
advantages
including
activity
fewer
office
visits
less
contact
patients
eyes
face
hope
continue
momentum
fourth
quarter
recent
commercial
alliance
imprimisrx
dexycu
increased
physician
education
estimated
net
product
revenue
third
quarter
ended
september
consists
million
yutiq
million
dexycu
customer
demand
yutiq
represented
units
purchased
physicians
company
distributors
approximately
units
compared
units
customer
demand
dexycu
represented
units
purchased
ambulatory
surgery
centers
company
distributors
approximately
units
compared
units
preliminary
third
quarter
net
product
revenue
results
included
release
calculated
prior
completion
review
company
independent
registered
public
accounting
firm
therefore
subject
adjustment
company
plans
provide
additional
financial
information
including
total
revenue
third
quarter
financial
results
release
expected
november
eyepoint
pharmaceuticals
eyepoint
pharmaceuticals
pharmaceutical
company
committed
developing
commercializing
innovative
ophthalmic
products
indications
high
unmet
medical
need
help
improve
lives
patients
serious
eye
disorders
company
currently
two
commercial
products
first
approved
intraocular
product
treatment
postoperative
inflammation
treatment
chronic
uveitis
affecting
posterior
segment
eye
company
pipeline
leverages
proprietary
bioerodible
technology
extended
intraocular
drug
delivery
including
potential
therapy
initially
targeting
wet
macular
degeneration
eyepoint
pharmaceuticals
headquartered
watertown
massachusetts
offices
basking
ridge
new
jersey
learn
company
please
visit
connect
twitter
linkedin
safe
harbor
statements
private
securities
litigation
act
various
statements
made
release
inherently
subject
risks
uncertainties
potentially
inaccurate
assumptions
statements
address
activities
events
developments
intend
expect
plan
believe
may
occur
future
including
limited
statements
expectations
regarding
extent
business
could
adversely
impacted
effects
coronavirus
pandemic
well
timing
clinical
development
product
candidates
including
potential
vital
novel
treatment
serious
eye
diseases
including
wet
macular
degeneration
diabetic
retinopathy
retinal
vein
occlusion
factors
could
cause
actual
results
differ
materially
anticipated
results
expectations
expressed
anticipated
implied
statements
risks
uncertainties
inherent
business
including
without
limitation
extent
impacts
business
effectiveness
timeliness
clinical
trials
usefulness
data
timeliness
regulatory
approvals
ability
achieve
profitable
operations
access
needed
capital
fluctuations
operating
results
ability
successfully
produce
sufficient
commercial
quantities
yutiq
dexycu
successfully
commercialize
yutiq
dexycu
ability
sustain
enhance
effective
commercial
infrastructure
enter
maintain
commercial
agreements
yutiq
dexycu
development
yutiq
line
extension
treatment
uveitis
affecting
posterior
segment
eye
potential
sales
iluvien
uveitis
affecting
posterior
segment
eye
consequences
fluocinolone
acetonide
side
effects
yutiq
consequences
dexamethasone
side
effects
dexycu
successful
commercialization
receipt
revenues
iluvien
diabetic
macular
edema
dme
alimera
ability
obtain
additional
marketing
approvals
effect
pricing
reimbursement
decisions
sales
iluvien
dme
alimera
ability
commercialize
iluvien
uveitis
affecting
posterior
segment
eye
territories
alimera
licensed
ability
market
sell
products
success
current
future
license
agreements
including
agreement
equinox
science
termination
breach
current
license
agreements
including
agreement
equinox
science
dependence
contract
research
organizations
contract
sales
organizations
vendors
investigators
effects
competition
developments
affecting
sales
products
market
acceptance
products
effects
guidelines
recommendations
studies
protection
intellectual
property
avoiding
intellectual
property
infringement
retention
key
personnel
product
liability
industry
consolidation
compliance
environmental
laws
manufacturing
risks
risks
costs
international
business
operations
volatility
stock
price
possible
dilution
absence
dividends
factors
described
filings
securities
exchange
commission
guarantee
results
expectations
expressed
anticipated
implied
statement
realized
variety
factors
including
risks
could
cause
actual
results
expectations
differ
materially
anticipated
results
expectations
expressed
anticipated
implied
statements
known
unknown
risks
materialize
underlying
assumptions
prove
inaccurate
actual
results
could
differ
materially
past
results
anticipated
estimated
projected
statements
bear
mind
consider
statements
statements
speak
dates
made
undertake
obligation
publicly
update
revise
statements
even
experience
future
changes
makes
clear
projected
results
expressed
implied
statements
realized
contacts
investors
argot
partners
sam
martin
joe
rayne
eyepoint
media
thomas
gibson
tom
